Results of a study led by researchers at Roswell Park Comprehensive Cancer Center are shedding light on why some newly diagnosed glioblastoma patients survive longer than others after receiving standard treatment in conjunction with the therapeutic brain cancer immunotherapy SurVaxM. The team’s findings, newly reported in the journal Cancer Immunology & Immunotherapy, linked long-term survival to the tumor’s molecular characteristics prior to treatment.
This post was originally published on this site
